Treatment of refractory cardiac arrest requiring cardiopulmonary resuscitation (CPR) may be augmented with Extracorporeal membrane oxygenation (ECMO) to re-establish perfusion in the absence of return of spontaneous circulation. Literature has demonstrated that ECMO initiated during advanced cardiopulmonary life support may confer superior survival rates with acceptable survival and a relatively low incidence of significant neurologic impairment. Levosimendan has not been investigated in patients with cardiac arrest who underwent Extracorporeal CPR (E-CPR). The current study aims to examine whether levosimendan use in the aforementioned patient population could improve survival and ECMO parameters.
Study Type
OBSERVATIONAL
Enrollment
100
examine whether levosimendan could improve in-hospital survival with good neurological outcomes in patients with cardiac arrest supported by E-CPR
Hamad medical corporation
Doha, DA, Qatar
RECRUITINGSurvival to hospital discharge
Survival to hospital discharge with good neurological outcomes
Time frame: 6 months
Survival to decannulation
Survival to decannulation with good neurological outcomes
Time frame: 6 months
long term survival
long term survival
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.